Please use this identifier to cite or link to this item: https://ninho.inca.gov.br/jspui/handle/123456789/5398
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPaulino, Eduardo-
dc.contributor.authorMelo, Andreia Cristina de-
dc.contributor.authorSilva Filho, Agnaldo Lopes-
dc.contributor.authorMaciel, Luiza de Freitas-
dc.contributor.authorThuler, Luiz Claudio Santos-
dc.contributor.authorGoss, Paul Edward-
dc.contributor.authorRodrigues, Angélica Nogueira-
dc.date.accessioned2022-03-03T18:40:20Z-
dc.date.available2022-03-03T18:40:20Z-
dc.date.issued2020-
dc.identifier.citationPAULINO, Eduardo et al. Panorama of gynecologic cancer in Brazil. JCO Global Oncology, n. 6, p. 1617-1630, 2020.-
dc.identifier.urihttp://sr-vmlxaph03:8080/jspui/handle/123456789/5398-
dc.descriptionp. 1617-1630.: il. p&b.-
dc.description.abstractLittle is known, or has been published previously, regarding consolidated data on the epidemiology of gynecologic cancers (GC) in Brazil. This article describes the incidence, morbidity, and mortality of women in Brazil affected with GC between the years of 2000 and 2017. METHODS Incidence, morbidity, and mortality data from patients with a diagnosis of one out of the five most common GC, cervical (CC), uterine (UC), ovarian (OC), vulvar (VvC), and vaginal (VgC), were obtained from three governamental sources of data. RESULTS From 2000 to 2015 CC, OC, and VgC incidence rates (IRs) decreased, whereas the IRs for UC and VvC remained relatively stable. Data from 382,932 women with GC were analyzed. Most patients presented with locally advanced or advanced disease at diagnosis: 60.1% of patients with CC, 31.2% of patients with UC, 67.2% of patients with OC, 45.2% of patients with VvC, and 67.0% of patients with VgC. Time from diagnosis to first treatment was ≥ 60 days in 58.0% of patients with CC, 58.5% of patients with UC, 27.0% of patients with OC, 55.3% of patients with VvC, and 52.7% of patients with VgC. Regarding mortality rates (MRs), with the exception of CC, UC, and VvC, which showed a slight decrease, MRs remained stable between 2000 and 2017. CONCLUSION A comparison with international data indicates that Brazilian patients are diagnosed with more advanced disease and face a longer delay between diagnosis and first treatment. Despite advances in screening and treatment, GC mortality has not decreased satisfactorily in this country.-
dc.publisherJCO Global Oncologypt_BR
dc.subjectNeoplasias dos Genitais Femininospt_BR
dc.subjectGenital Neoplasms Femalept_BR
dc.subjectApresentação de Dadospt_BR
dc.subjectData Displaypt_BR
dc.subjectIncidênciapt_BR
dc.subjectIncidencept_BR
dc.subjectMorbidadept_BR
dc.subjectMorbiditypt_BR
dc.subjectMortalidadept_BR
dc.subjectMortalitypt_BR
dc.subjectMetanálise como Assuntopt_BR
dc.subjectMeta-Analysis as Topicpt_BR
dc.titlePanorama of gynecologic cancer in Brazilpt_BR
dc.TypeArticlept_BR
Appears in Collections:Artigos de Periódicos da área de Oncologia Clínica

Files in This Item:
File Description SizeFormat 
Panorama of Gynecologic Cancer in Brazil.pdf781.43 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.